English

CLARUS THERAPEUTICS HOLDINGS, INC.

EDGAR

BLUW Quarterly report (10-Q) · filed 2022-08-19

15 filing records in this dataset, filed from 2020-09-03 to 2022-08-19. Reported financial figures are available; chart coverage varies by period.

Inspect reported changes Compare with another company Historical disclosures Search filings Segments

Watchlist

Latest quarter

Revenue

4.05 million USD

2022 Q2 · USD

Exact inputs and evidence

Revenue: 4050000 USD Source

Net margin

-264.05%

2022 Q2 · %

Exact inputs and evidence

Net Income: -10694000 USD Source
Revenue: 4050000 USD Source

Operating cash flow

-17.5 million USD

2022 Q2 · USD

Exact inputs and evidence

Operating Cash Flow: -34769000 USD Source
Operating Cash Flow: -17268000 USD Source

Free cash flow

-17.5 million USD

2022 Q2 · USD

Exact inputs and evidence

Operating Cash Flow: -34769000 USD Source
Operating Cash Flow: -17268000 USD Source
Capital Expenditure: 10000 USD Source
Capital Expenditure: 10000 USD Source

Cash and cash equivalents: 19.2 million USD 2022-06-30 Source
Exact value

19200000 USD
Long-term debt including current maturities: 78.7 million USD 2021-06-30 Source
Exact value

78722000 USD
Shares outstanding: 52 million shares 2022-06-30 Source
Exact value

52020731 shares

Reported share-count change

1,385.95% · 48.5 million shares

Year-over-year change in reported shares. Splits, issuance and buybacks can affect this figure; it does not isolate employee compensation or economic dilution.

Exact inputs and evidence

3500848 shares · 2021-06-30· Source
52020731 shares · 2022-06-30· Source

Trailing twelve months

The four most recent complete quarters added together. This gives a full-year view that includes the latest quarterly results.

Revenue

16.9 million USD

2021-07-01 – 2022-06-30

Exact inputs and evidence

Revenue: 4286000 USD · 2021-07-01 – 2021-09-30 Source
Revenue: 13957000 USD · 2021-01-01 – 2021-12-31 Source
Revenue: 9395000 USD · 2021-01-01 – 2021-09-30 Source
Revenue: 4011000 USD · 2022-01-01 – 2022-03-31 Source
Revenue: 4050000 USD · 2022-04-01 – 2022-06-30 Source

Net income

-32.6 million USD

2021-07-01 – 2022-06-30

Exact inputs and evidence

Net income: -2769000 USD · 2021-07-01 – 2021-09-30 Source
Net income: -40617000 USD · 2021-01-01 – 2021-12-31 Source
Net income: -36315000 USD · 2021-01-01 – 2021-09-30 Source
Net income: -14870000 USD · 2022-01-01 – 2022-03-31 Source
Net income: -10694000 USD · 2022-04-01 – 2022-06-30 Source

Capital expenditure

15 thousand USD

2021-07-01 – 2022-06-30

Exact inputs and evidence

Capital expenditure: 20000 USD · 2021-01-01 – 2021-09-30 Source
Capital expenditure: 20000 USD · 2021-01-01 – 2021-06-30 Source
Capital expenditure: 25000 USD · 2021-01-01 – 2021-12-31 Source
Capital expenditure: 20000 USD · 2021-01-01 – 2021-09-30 Source
Capital expenditure: 10000 USD · 2022-01-01 – 2022-03-31 Source
Capital expenditure: 10000 USD · 2022-01-01 – 2022-06-30 Source
Capital expenditure: 10000 USD · 2022-01-01 – 2022-03-31 Source

Includes later revisions to earlier periods. Annual charts exclude incomplete years.

Latest filing recorded: 2022-08-19.

Financial data available through: 2021-12-31.

Coverage by financial measure

Revenue: 2 of 11 periods available· newest 2021-12-31
operating income: No compatible figures in this window
Net income: 3 of 11 periods available· newest 2021-12-31
Operating cash flow: 3 of 11 periods available· newest 2021-12-31
Capital expenditure: 3 of 11 periods available· newest 2021-12-31
Total assets: 2 of 11 periods available· newest 2021-12-31
Total liabilities: 2 of 11 periods available· newest 2021-12-31
Current assets: 2 of 11 periods available· newest 2021-12-31
Current liabilities: 2 of 11 periods available· newest 2021-12-31
Cash and cash equivalents: 2 of 11 periods available· newest 2021-12-31
Long-term debt including current maturities: 1 of 11 periods available· newest 2020-12-31
Shares outstanding: 2 of 11 periods available· newest 2021-12-31

Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.

What changed year over year

Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.

Revenue
+119.1%

Prior period

USD 6.37 million

2020-01-01 – 2020-12-31
Current period

USD 13.96 million

2021-01-01 – 2021-12-31

Exact inputs and evidence

13957000 − 6369000 = 7588000 USD

6369000 USD · 2020-01-01 – 2020-12-31
Inspect prior input Prior source
13957000 USD · 2021-01-01 – 2021-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Revenue · CLARUS THERAPEUTICS HOLDINGS, INC. · 2021-12-31 CLARUS THERAPEUTICS HOLDINGS, INC. (edgar:1817944) Year-over-year change in Revenue: 7588000 USD Concept: fundies:Revenue Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T23:21:40Z Snapshot: f38f591482250009eb5445e306a2253f3200a7abe2e3bacc3c802f3999902289 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1817944?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:Revenue: 13957000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1817944/000119312522158662/d282443ds1.htm#2436382 Filing: 000119312522158662 Input fundies:Revenue: 6369000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1817944/000119312522158662/d282443ds1.htm#2436827 Filing: 000119312522158662
The citation records this snapshot. The page link may show a newer release later.
Net income
-1,034.8%

Prior period

USD 4.35 million

2020-01-01 – 2020-12-31
Current period

−USD 40.62 million

2021-01-01 – 2021-12-31

Exact inputs and evidence

-40617000 − 4345000 = -44962000 USD

4345000 USD · 2020-01-01 – 2020-12-31
Inspect prior input Prior source
-40617000 USD · 2021-01-01 – 2021-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Net income · CLARUS THERAPEUTICS HOLDINGS, INC. · 2021-12-31 CLARUS THERAPEUTICS HOLDINGS, INC. (edgar:1817944) Year-over-year change in Net income: -44962000 USD Concept: fundies:NetIncome Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T23:21:40Z Snapshot: f38f591482250009eb5445e306a2253f3200a7abe2e3bacc3c802f3999902289 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1817944?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:NetIncome: -40617000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1817944/000119312522158662/d282443ds1.htm#3256268 Filing: 000119312522158662 Input fundies:NetIncome: 4345000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1817944/000119312522158662/d282443ds1.htm#3256902 Filing: 000119312522158662
The citation records this snapshot. The page link may show a newer release later.
Operating cash flow
−USD 2.21 million

Prior period

−USD 41.58 million

2020-01-01 – 2020-12-31
Current period

−USD 43.79 million

2021-01-01 – 2021-12-31

Exact inputs and evidence

-43786000 − -41580000 = -2206000 USD

-41580000 USD · 2020-01-01 – 2020-12-31
Inspect prior input Prior source
-43786000 USD · 2021-01-01 – 2021-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Operating cash flow · CLARUS THERAPEUTICS HOLDINGS, INC. · 2021-12-31 CLARUS THERAPEUTICS HOLDINGS, INC. (edgar:1817944) Year-over-year change in Operating cash flow: -2206000 USD Concept: fundies:OperatingCashFlow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T23:21:40Z Snapshot: f38f591482250009eb5445e306a2253f3200a7abe2e3bacc3c802f3999902289 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1817944?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:OperatingCashFlow: -43786000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1817944/000119312522158662/d282443ds1.htm#2627493 Filing: 000119312522158662 Input fundies:OperatingCashFlow: -41580000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1817944/000119312522158662/d282443ds1.htm#2627988 Filing: 000119312522158662
The citation records this snapshot. The page link may show a newer release later.
Capital expenditure
-60.3%

Prior period

USD 63,000

2020-01-01 – 2020-12-31
Current period

USD 25,000

2021-01-01 – 2021-12-31

Exact inputs and evidence

25000 − 63000 = -38000 USD

63000 USD · 2020-01-01 – 2020-12-31
Inspect prior input Prior source
25000 USD · 2021-01-01 – 2021-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Capital expenditure · CLARUS THERAPEUTICS HOLDINGS, INC. · 2021-12-31 CLARUS THERAPEUTICS HOLDINGS, INC. (edgar:1817944) Year-over-year change in Capital expenditure: -38000 USD Concept: fundies:CapitalExpenditure Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T23:21:40Z Snapshot: f38f591482250009eb5445e306a2253f3200a7abe2e3bacc3c802f3999902289 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1817944?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:CapitalExpenditure: 25000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1817944/000119312522158662/d282443ds1.htm#2630274 Filing: 000119312522158662 Input fundies:CapitalExpenditure: 63000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1817944/000119312522158662/d282443ds1.htm#2630756 Filing: 000119312522158662
The citation records this snapshot. The page link may show a newer release later.

Where revenue goes

How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.

2021 2021-01-01 – 2021-12-31

Revenue USD 13.96 million 100% of revenue
Operating costs Derived Unavailable An input is unavailable.
Operating income Unavailable An input is unavailable.
Tax, interest and other Derived Unavailable An input is unavailable.
Net income −USD 40.62 million −291% of revenue

Cash

Operating cash flow −USD 43.79 million −314% of revenue
Capital expenditure USD 25,000 0.2% of revenue
Free cash flow Derived −USD 43.81 million −314% of revenue

Share of revenue by period

Net income
Tax, interest and other
Operating costs

2020 Not shown: operating income or net income is not reported.
2021 Not shown: operating income or net income is not reported.

Values and sources

Revenue breakdown by annual reporting period
Period	Revenue	Operating costs	Operating income	Tax, interest and other	Net income	Free cash flow	Source
2020 2020-01-01 – 2020-12-31	6369000	Unavailable	Unavailable	Unavailable	4345000	-41643000 Derived	Source 2020-01-01 – 2020-12-31: 6369000 USD Inspect Revenue Open source 2020-01-01 – 2020-12-31: 4345000 USD Inspect Net Income Open source 2020-01-01 – 2020-12-31: -41580000 USD Inspect Operating Cash Flow Open source 2020-01-01 – 2020-12-31: 63000 USD Inspect Capital Expenditure Open source
2021 2021-01-01 – 2021-12-31	13957000	Unavailable	Unavailable	Unavailable	-40617000	-43811000 Derived	Source 2021-01-01 – 2021-12-31: 13957000 USD Inspect Revenue Open source 2021-01-01 – 2021-12-31: -40617000 USD Inspect Net Income Open source 2021-01-01 – 2021-12-31: -43786000 USD Inspect Operating Cash Flow Open source 2021-01-01 – 2021-12-31: 25000 USD Inspect Capital Expenditure Open source

Amounts are exact, in USD.

Growth

Sales over time and how quickly they are changing.

Revenue

Revenue reported for each complete financial period.

USD 14M 2021

Values and sources

Revenue values and source evidence
Period	Series	Value(USD)	Source evidence
20202020-12-31	Revenue	6369000	Revenue: 6369000 Open source
20212021-12-31	Revenue	13957000	Revenue: 13957000 Open source

Revenue growth

Change in revenue from the same financial period one year earlier.

119.1% 2021

Values and sources

Revenue growth values and source evidence
Period	Series	Value	Source evidence
20202020-12-31	Year over year	No prior comparable period	Revenue: 6369000 Open source
20212021-12-31	Year over year	119.1%	Revenue: 13957000 Open source Revenue: 6369000 Open source

Profit and cash

How much revenue becomes profit, and how much cash operations generate.

Profit margins

Operating income, net income and free cash flow as a share of revenue.

Net margin -291% 2021

Free cash flow margin -313.9% 2021

Operating margin
Net margin
Free cash flow margin

Values and sources

Profit margins values and source evidence
Period	Series	Value	Source evidence
2020-12-31	Operating margin	Not reported	Revenue: 6369000 Open source
2021-12-31	Operating margin	Not reported	Revenue: 13957000 Open source
20202020-12-31	Net margin	68.2%	Net Income: 4345000 Open source Revenue: 6369000 Open source
20212021-12-31	Net margin	-291%	Net Income: -40617000 Open source Revenue: 13957000 Open source
20202020-12-31	Free cash flow margin	-653.8%	Revenue: 6369000 Open source Operating Cash Flow: -41580000 Open source Capital Expenditure: 63000 Open source
20212021-12-31	Free cash flow margin	-313.9%	Revenue: 13957000 Open source Operating Cash Flow: -43786000 Open source Capital Expenditure: 25000 Open source

Operating cash flow

Cash generated by the company’s normal business operations.

USD -43.8M 2021

Values and sources

Operating cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20202020-12-31	Operating cash flow	-41580000	Operating Cash Flow: -41580000 Open source
20212021-12-31	Operating cash flow	-43786000	Operating Cash Flow: -43786000 Open source

Free cash flow

Operating cash flow minus capital expenditure for the same period and unit.

USD -43.8M 2021

Values and sources

Free cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20202020-12-31	Free cash flow	-41643000	Operating Cash Flow: -41580000 Open source Capital Expenditure: 63000 Open source
20212021-12-31	Free cash flow	-43811000	Operating Cash Flow: -43786000 Open source Capital Expenditure: 25000 Open source

Balance sheet

Liabilities and short-term ability to meet obligations at each period end.

Liabilities to assets

Total liabilities as a share of total assets.

130.8% 2021

Values and sources

Liabilities to assets values and source evidence
Period	Series	Value	Source evidence
20202020-12-31	Liabilities / assets	757.7%	Total Liabilities: 146985000 Open source Total Assets: 19400000 Open source
20212021-12-31	Liabilities / assets	130.8%	Total Liabilities: 67627000 Open source Total Assets: 51708000 Open source

Current assets to current liabilities

Current assets divided by current liabilities.

0.78× 2021

Values and sources

Current assets to current liabilities values and source evidence
Period	Series	Value	Source evidence
20202020-12-31	Current assets / current liabilities	0.32×	Current Assets: 19336000 Open source Current Liabilities: 59812000 Open source
20212021-12-31	Current assets / current liabilities	0.78×	Current Assets: 51643000 Open source Current Liabilities: 66060000 Open source

Cash generation

Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.

Cash generation by annual reporting period
Period	Net income	Operating cash flow	Capital expenditure	Free cash flow
2019 2019-01-01 – 2019-12-31	−USD 41.65 million Exact value Exact value: -41650000 USD 2019-01-01 – 2019-12-31: -41650000 USD Inspect Net Income Open source Share or cite Citation for Net Income · CLARUS THERAPEUTICS HOLDINGS, INC. · 2019-12-31 CLARUS THERAPEUTICS HOLDINGS, INC. (edgar:1817944) Net Income: -41650000 USD Concept: fundies:NetIncome Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T23:21:40Z Snapshot: f38f591482250009eb5445e306a2253f3200a7abe2e3bacc3c802f3999902289 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1817944/explain?concept=fundies%3ANetIncome&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:NetIncome: -41650000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1817944/000119312521361352/d262025ds1.htm#2687380 Filing: 000119312521361352 The citation records this snapshot. The page link may show a newer release later.	−USD 19.72 million Exact value Exact value: -19715000 USD 2019-01-01 – 2019-12-31: -19715000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · CLARUS THERAPEUTICS HOLDINGS, INC. · 2019-12-31 CLARUS THERAPEUTICS HOLDINGS, INC. (edgar:1817944) Operating Cash Flow: -19715000 USD Concept: fundies:OperatingCashFlow Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T23:21:40Z Snapshot: f38f591482250009eb5445e306a2253f3200a7abe2e3bacc3c802f3999902289 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1817944/explain?concept=fundies%3AOperatingCashFlow&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -19715000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1817944/000119312521361352/d262025ds1.htm#2707403 Filing: 000119312521361352 The citation records this snapshot. The page link may show a newer release later.	USD 21,000 Exact value Exact value: 21000 USD 2019-01-01 – 2019-12-31: 21000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · CLARUS THERAPEUTICS HOLDINGS, INC. · 2019-12-31 CLARUS THERAPEUTICS HOLDINGS, INC. (edgar:1817944) Capital Expenditure: 21000 USD Concept: fundies:CapitalExpenditure Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T23:21:40Z Snapshot: f38f591482250009eb5445e306a2253f3200a7abe2e3bacc3c802f3999902289 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1817944/explain?concept=fundies%3ACapitalExpenditure&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 21000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1817944/000119312521361352/d262025ds1.htm#2710009 Filing: 000119312521361352 The citation records this snapshot. The page link may show a newer release later.	−USD 19.74 million Calculation and evidence -19715000 − 21000 USD Exact free cash flow: -19736000 USD 2019-01-01 – 2019-12-31: -19715000 USD · Inspect Operating Cash Flow · Source 2019-01-01 – 2019-12-31: 21000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · CLARUS THERAPEUTICS HOLDINGS, INC. · 2019-12-31 CLARUS THERAPEUTICS HOLDINGS, INC. (edgar:1817944) Free cash flow: -19736000 USD Concept: free-cash-flow Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T23:21:40Z Snapshot: f38f591482250009eb5445e306a2253f3200a7abe2e3bacc3c802f3999902289 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1817944?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -19715000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1817944/000119312521361352/d262025ds1.htm#2707403 Filing: 000119312521361352 Input fundies:CapitalExpenditure: 21000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1817944/000119312521361352/d262025ds1.htm#2710009 Filing: 000119312521361352 The citation records this snapshot. The page link may show a newer release later.
2020 2020-01-01 – 2020-12-31	USD 4.35 million Exact value Exact value: 4345000 USD 2020-01-01 – 2020-12-31: 4345000 USD Inspect Net Income Open source Share or cite Citation for Net Income · CLARUS THERAPEUTICS HOLDINGS, INC. · 2020-12-31 CLARUS THERAPEUTICS HOLDINGS, INC. (edgar:1817944) Net Income: 4345000 USD Concept: fundies:NetIncome Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T23:21:40Z Snapshot: f38f591482250009eb5445e306a2253f3200a7abe2e3bacc3c802f3999902289 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1817944/explain?concept=fundies%3ANetIncome&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:NetIncome: 4345000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1817944/000119312522158662/d282443ds1.htm#3256902 Filing: 000119312522158662 The citation records this snapshot. The page link may show a newer release later.	−USD 41.58 million Exact value Exact value: -41580000 USD 2020-01-01 – 2020-12-31: -41580000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · CLARUS THERAPEUTICS HOLDINGS, INC. · 2020-12-31 CLARUS THERAPEUTICS HOLDINGS, INC. (edgar:1817944) Operating Cash Flow: -41580000 USD Concept: fundies:OperatingCashFlow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T23:21:40Z Snapshot: f38f591482250009eb5445e306a2253f3200a7abe2e3bacc3c802f3999902289 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1817944/explain?concept=fundies%3AOperatingCashFlow&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -41580000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1817944/000119312522158662/d282443ds1.htm#2627988 Filing: 000119312522158662 The citation records this snapshot. The page link may show a newer release later.	USD 63,000 Exact value Exact value: 63000 USD 2020-01-01 – 2020-12-31: 63000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · CLARUS THERAPEUTICS HOLDINGS, INC. · 2020-12-31 CLARUS THERAPEUTICS HOLDINGS, INC. (edgar:1817944) Capital Expenditure: 63000 USD Concept: fundies:CapitalExpenditure Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T23:21:40Z Snapshot: f38f591482250009eb5445e306a2253f3200a7abe2e3bacc3c802f3999902289 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1817944/explain?concept=fundies%3ACapitalExpenditure&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 63000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1817944/000119312522158662/d282443ds1.htm#2630756 Filing: 000119312522158662 The citation records this snapshot. The page link may show a newer release later.	−USD 41.64 million Calculation and evidence -41580000 − 63000 USD Exact free cash flow: -41643000 USD 2020-01-01 – 2020-12-31: -41580000 USD · Inspect Operating Cash Flow · Source 2020-01-01 – 2020-12-31: 63000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · CLARUS THERAPEUTICS HOLDINGS, INC. · 2020-12-31 CLARUS THERAPEUTICS HOLDINGS, INC. (edgar:1817944) Free cash flow: -41643000 USD Concept: free-cash-flow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T23:21:40Z Snapshot: f38f591482250009eb5445e306a2253f3200a7abe2e3bacc3c802f3999902289 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1817944?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -41580000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1817944/000119312522158662/d282443ds1.htm#2627988 Filing: 000119312522158662 Input fundies:CapitalExpenditure: 63000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1817944/000119312522158662/d282443ds1.htm#2630756 Filing: 000119312522158662 The citation records this snapshot. The page link may show a newer release later.
2021 2021-01-01 – 2021-12-31	−USD 40.62 million Exact value Exact value: -40617000 USD 2021-01-01 – 2021-12-31: -40617000 USD Inspect Net Income Open source Share or cite Citation for Net Income · CLARUS THERAPEUTICS HOLDINGS, INC. · 2021-12-31 CLARUS THERAPEUTICS HOLDINGS, INC. (edgar:1817944) Net Income: -40617000 USD Concept: fundies:NetIncome Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T23:21:40Z Snapshot: f38f591482250009eb5445e306a2253f3200a7abe2e3bacc3c802f3999902289 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1817944/explain?concept=fundies%3ANetIncome&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:NetIncome: -40617000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1817944/000119312522158662/d282443ds1.htm#3256268 Filing: 000119312522158662 The citation records this snapshot. The page link may show a newer release later.	−USD 43.79 million Exact value Exact value: -43786000 USD 2021-01-01 – 2021-12-31: -43786000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · CLARUS THERAPEUTICS HOLDINGS, INC. · 2021-12-31 CLARUS THERAPEUTICS HOLDINGS, INC. (edgar:1817944) Operating Cash Flow: -43786000 USD Concept: fundies:OperatingCashFlow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T23:21:40Z Snapshot: f38f591482250009eb5445e306a2253f3200a7abe2e3bacc3c802f3999902289 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1817944/explain?concept=fundies%3AOperatingCashFlow&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -43786000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1817944/000119312522158662/d282443ds1.htm#2627493 Filing: 000119312522158662 The citation records this snapshot. The page link may show a newer release later.	USD 25,000 Exact value Exact value: 25000 USD 2021-01-01 – 2021-12-31: 25000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · CLARUS THERAPEUTICS HOLDINGS, INC. · 2021-12-31 CLARUS THERAPEUTICS HOLDINGS, INC. (edgar:1817944) Capital Expenditure: 25000 USD Concept: fundies:CapitalExpenditure Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T23:21:40Z Snapshot: f38f591482250009eb5445e306a2253f3200a7abe2e3bacc3c802f3999902289 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1817944/explain?concept=fundies%3ACapitalExpenditure&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 25000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1817944/000119312522158662/d282443ds1.htm#2630274 Filing: 000119312522158662 The citation records this snapshot. The page link may show a newer release later.	−USD 43.81 million Calculation and evidence -43786000 − 25000 USD Exact free cash flow: -43811000 USD 2021-01-01 – 2021-12-31: -43786000 USD · Inspect Operating Cash Flow · Source 2021-01-01 – 2021-12-31: 25000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · CLARUS THERAPEUTICS HOLDINGS, INC. · 2021-12-31 CLARUS THERAPEUTICS HOLDINGS, INC. (edgar:1817944) Free cash flow: -43811000 USD Concept: free-cash-flow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T23:21:40Z Snapshot: f38f591482250009eb5445e306a2253f3200a7abe2e3bacc3c802f3999902289 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1817944?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -43786000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1817944/000119312522158662/d282443ds1.htm#2627493 Filing: 000119312522158662 Input fundies:CapitalExpenditure: 25000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1817944/000119312522158662/d282443ds1.htm#2630274 Filing: 000119312522158662 The citation records this snapshot. The page link may show a newer release later.

Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.

Dataset coverage and company identifiers

Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.

15 filings · 577 latest values · 577 originally reported values

Dataset published 2026-11-02. Source filing dates and reporting periods are shown separately.

Identifiers: 0001817944, 1817944, BLUW, CRXT, edgar:1817944

Also known as BLUE WATER ACQUISITION CORP., Blue Water Acquisition Corp., CLARUS THERAPEUTICS HOLDINGS, INC., Clarus Therapeutics Holdings, Inc.

CLARUS THERAPEUTICS HOLDINGS, INC.

Latest quarter

Revenue

Net margin

Operating cash flow

Free cash flow

Reported share-count change

Trailing twelve months

Revenue

Net income

Capital expenditure

Company performance

What changed year over year

Revenue

Net income

Operating cash flow

Capital expenditure

Where revenue goes

2021 2021-01-01 – 2021-12-31

Cash

Share of revenue by period

Growth

Profit and cash

Balance sheet

Cash generation